KPIs & Operating Metrics(New)
Biopharma Testing VolumeBreakdown Of AssetsClinical VolumeContractual ObligationsCost Of RevenueCost Of Revenue By SegmentDeferred RevenueEmployee StatisticsGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome Before Provision For Income TaxesNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of RevenueOPEX BreakdownProperty And Equipment, NetRevenueRevenue By RegionRevenue By Region %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Guardant Health (GH) Gross Profit (2025)

Guardant Health's Gross Profit history spans 9 years, with the latest figure at $632.5 million for Q4 2025.

  • On a quarterly basis, Gross Profit rose 1188.67% to $632.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $982.0 million, a 173.58% increase, with the full-year FY2025 number at $982.0 million, up 162.52% from a year prior.
  • Gross Profit hit $632.5 million in Q4 2025 for Guardant Health, up from $137.8 million in the prior quarter.
  • Over the last five years, Gross Profit for GH hit a ceiling of $632.5 million in Q4 2025 and a floor of $31.7 million in Q1 2022.
  • Historically, Gross Profit has averaged $107.7 million across 5 years, with a median of $59.3 million in 2023.
  • Biggest five-year swings in Gross Profit: plummeted 82.94% in 2024 and later soared 1188.67% in 2025.
  • Tracing GH's Gross Profit over 5 years: stood at $48.5 million in 2021, then decreased by 6.27% to $45.5 million in 2022, then skyrocketed by 532.87% to $287.8 million in 2023, then plummeted by 82.94% to $49.1 million in 2024, then soared by 1188.67% to $632.5 million in 2025.
  • Business Quant data shows Gross Profit for GH at $632.5 million in Q4 2025, $137.8 million in Q3 2025, and $112.5 million in Q2 2025.